GPCR NewsSep 1, 20221 minGPCRs in Oncology and ImmunologyNovel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patientsSeptember 2022 "Background Cancer driver genes are usually ranked by mutation frequency, which does not necessarily reflect their driver...
GPCR NewsSep 1, 20221 minGPCRs in Oncology and ImmunologyGPR108 is required for gambogic acid inhibiting NF-κB signaling in cancerSeptember 2022 "GPCRs are the most potential targets for drug discovery, however, their role in oncology is underappreciated and...
GPCR NewsAug 1, 20221 minGPCRs in Oncology and ImmunologyMSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?August 2022 "Chemokines, a subgroup of cytokines along with their receptors, are involved in various biologic processes and regulation of...
GPCR NewsAug 1, 20221 minGPCR Industry NewsAnatomy of a partnership: Cancer Research UK teams up with Sosei HeptaresAugust 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring...
GPCR NewsJul 1, 20221 minGPCR Industry NewsCancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ... July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials "HTL0039732...
GPCR NewsDec 1, 20211 minGPCR Binders, Drugs, and moreThe development of modulators for lysophosphatidic acid receptors: A comprehensive reviewLysophosphatidic acids (LPAs) are bioactive phospholipids implicated in a wide range of cellular activities that regulate a diverse array...